Moreover, the 36-month beta value for BCDA is 1.22. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCDA is 3.70M and currently, short sellers hold a 1.35% of that float. On March 31, 2025, BCDA’s average trading volume was 48.62K shares.
BCDA) stock’s latest price update
The stock of BioCardia Inc (NASDAQ: BCDA) has increased by 4.48 when compared to last closing price of 2.68.Despite this, the company has seen a gain of 5.26% in its stock price over the last five trading days. globenewswire.com reported 2025-03-26 that SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission.
BCDA’s Market Performance
BCDA’s stock has risen by 5.26% in the past week, with a monthly rise of 37.25% and a quarterly rise of 40.00%. The volatility ratio for the week is 9.34% while the volatility levels for the last 30 days are 8.73% for BioCardia Inc The simple moving average for the past 20 days is 7.90% for BCDA’s stock, with a 7.94% simple moving average for the past 200 days.
BCDA Trading at 14.53% from the 50-Day Moving Average
After a stumble in the market that brought BCDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.56% of loss for the given period.
Volatility was left at 8.73%, however, over the last 30 days, the volatility rate increased by 9.34%, as shares surge +39.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.70% upper at present.
During the last 5 trading sessions, BCDA rose by +5.26%, which changed the moving average for the period of 200-days by -18.37% in comparison to the 20-day moving average, which settled at $2.60. In addition, BioCardia Inc saw 28.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCDA starting from STERTZER SIMON H, who purchase 1,000 shares at the price of $2.45 back on Mar 05 ’25. After this action, STERTZER SIMON H now owns 57,138 shares of BioCardia Inc, valued at $2,450 using the latest closing price.
STERTZER SIMON H, the Director of BioCardia Inc, purchase 22,753 shares at $2.30 during a trade that took place back on Mar 03 ’25, which means that STERTZER SIMON H is holding 40,602 shares at $52,332 based on the most recent closing price.
Stock Fundamentals for BCDA
Current profitability levels for the company are sitting at:
- -137.95 for the present operating margin
- -2.66 for the gross margin
The net margin for BioCardia Inc stands at -137.0. The total capital return value is set at -5.7. Equity return is now at value -737.89, with -236.81 for asset returns.
Based on BioCardia Inc (BCDA), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -8.44.
Currently, EBITDA for the company is -7.93 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 201.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.13.
Conclusion
To wrap up, the performance of BioCardia Inc (BCDA) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
